203 related articles for article (PubMed ID: 8475072)
1. Inhibition of rate of tumor growth by creatine and cyclocreatine.
Miller EE; Evans AE; Cohn M
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3304-8. PubMed ID: 8475072
[TBL] [Abstract][Full Text] [Related]
2. Cyclocreatine in cancer chemotherapy.
Teicher BA; Menon K; Northey D; Liu J; Kufe DW; Kaddurah-Daouk R
Cancer Chemother Pharmacol; 1995; 35(5):411-6. PubMed ID: 7850923
[TBL] [Abstract][Full Text] [Related]
3. Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits growth of a broad spectrum of cancer cells derived from solid tumors.
Lillie JW; O'Keefe M; Valinski H; Hamlin HA; Varban ML; Kaddurah-Daouk R
Cancer Res; 1993 Jul; 53(13):3172-8. PubMed ID: 8319226
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of creatine analogs produced by alterations in pancreatic hormones and glucose metabolism.
Ara G; Gravelin LM; Kaddurah-Daouk R; Teicher BA
In Vivo; 1998; 12(2):223-31. PubMed ID: 9627806
[TBL] [Abstract][Full Text] [Related]
5. Creatine and cyclocreatine treatment of human colon adenocarcinoma xenografts: 31P and 1H magnetic resonance spectroscopic studies.
Kristensen CA; Askenasy N; Jain RK; Koretsky AP
Br J Cancer; 1999 Jan; 79(2):278-85. PubMed ID: 9888469
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells.
Hoosein NM; Martin KJ; Abdul M; Logothetis CJ; Kaddurah-Daouk R
Anticancer Res; 1995; 15(4):1339-42. PubMed ID: 7654018
[TBL] [Abstract][Full Text] [Related]
7. Myocardial protection during ischemia by prior feeding with the creatine analog: cyclocreatine.
Jacobstein MD; Gerken TA; Bhat AM; Carlier PG
J Am Coll Cardiol; 1989 Jul; 14(1):246-51. PubMed ID: 2738267
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts.
Evans AE; Kisselbach KD; Yamashiro DJ; Ikegaki N; Camoratto AM; Dionne CA; Brodeur GM
Clin Cancer Res; 1999 Nov; 5(11):3594-602. PubMed ID: 10589776
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of analgo of phosphocreatine in muscle of chicks fed 1-carboxymethyl-2-iminoimidazolidine (cyclocreatine).
Griffiths GR; Walker JB
J Biol Chem; 1976 Apr; 251(7):2049-54. PubMed ID: 1270421
[TBL] [Abstract][Full Text] [Related]
10. The synthetic phosphagen cyclocreatine phosphate inhibits the growth of a broad spectrum of solid tumors.
Schimmel L; Khandekar VS; Martin KJ; Riera T; Honan C; Shaw DG; Kaddurah-Daouk R
Anticancer Res; 1996; 16(1):375-80. PubMed ID: 8615639
[TBL] [Abstract][Full Text] [Related]
11. Cyclocreatine inhibits stimulated motility in tumor cells possessing creatine kinase.
Mulvaney PT; Stracke ML; Nam SW; Woodhouse E; O'Keefe M; Clair T; Liotta LA; Khaddurah-Daouk R; Schiffmann E
Int J Cancer; 1998 Sep; 78(1):46-52. PubMed ID: 9724093
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of growth inhibition of mammary carcinomas by glucarate and the glucarate: retinoid combination.
Webb TE; Abou-Issa H; Stromberg PC; Curley RC; Nguyen MH
Anticancer Res; 1993; 13(6A):2095-9. PubMed ID: 8297119
[TBL] [Abstract][Full Text] [Related]
13. Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats.
Saarinen NM; Wärri A; Dings RP; Airio M; Smeds AI; Mäkelä S
Int J Cancer; 2008 Sep; 123(5):1196-204. PubMed ID: 18528864
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of creatine analogues as a new class of anticancer agents using freshly explanted human tumor cells.
Martin KJ; Chen SF; Clark GM; Degen D; Wajima M; Von Hoff DD; Kaddurah-Daouk R
J Natl Cancer Inst; 1994 Apr; 86(8):608-13. PubMed ID: 8145276
[TBL] [Abstract][Full Text] [Related]
15. Effect of serial passage in nude athymic mice on the growth characteristics and chemotherapy responsiveness of 13762 and R3230AC mammary tumor xenografts.
Bogden AE; Kelton DE; Cobb WR; Gulkin TA; Johnson RK
Cancer Res; 1978 Jan; 38(1):59-64. PubMed ID: 618583
[No Abstract] [Full Text] [Related]
16. Electrophysiology and biochemical analysis of cyclocreatine uptake and effect in hippocampal slices.
Enrico A; Patrizia G; Luisa P; Alessandro P; Gianluigi L; Carlo G; Maurizio B
J Integr Neurosci; 2013 Jun; 12(2):285-97. PubMed ID: 23869866
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of chronic toxicity of cyclocreatine, a creatine analog, in Sprague Dawley rat after oral gavage administration for up to 26 weeks.
Kale VP; Wallery J; Novak J; Gibbs S; Bourdi M; Do MT; McKew JC; Terse PS
Regul Toxicol Pharmacol; 2020 Nov; 117():104750. PubMed ID: 32745584
[TBL] [Abstract][Full Text] [Related]
18. Effect of cyclocreatine feeding on levels of amino acids in rat hearts before and after an ischemic episode.
Osbakken M; Zhang DN; Nelson D; Erecińska M
Am J Physiol; 1991 Dec; 261(6 Pt 2):H1919-26. PubMed ID: 1684269
[TBL] [Abstract][Full Text] [Related]
19. Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors.
Schneider MR; Michna H; Nishino Y; Neef G; el Etreby MF
Anticancer Res; 1990; 10(3):683-7. PubMed ID: 2369083
[TBL] [Abstract][Full Text] [Related]
20. The novel tubulin-binding drug BTO-956 inhibits R3230AC mammary carcinoma growth and angiogenesis in Fischer 344 rats.
Shan S; Lockhart AC; Saito WY; Knapp AM; Laderoute KR; Dewhirst MW
Clin Cancer Res; 2001 Aug; 7(8):2590-6. PubMed ID: 11489843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
